A Study in People With Mild Hypertension

Protocol H8D-MC-EMBH PPAR Alpha (LY518674): a Phase 2 Dose-Response Study to Evaluate the Blood Pressure-Lowering Effect in Essential Hypertension

The primary objective of this study is to test the hypothesis that LY518674, administered for 6 weeks to patients with mild hypertension, reduces Systolic Blood Pressure, compared with placebo.

Inclusion Criteria:

1. Are men and women between 18 and 70 years of age, inclusive
2. Have given signed informed consent to participate in this study
3. Are diagnosed with mild essential hypertension at screening (currently untreated or treated with monotherapy)

Exclusion Criteria:

1. Secondary or malignant hypertension
2. Have or have had a history of hyperlipidemia within 3 months of screening requiring treatment
3. Any previous cardiovascular disease other than hypertension
4. Type 1 or 2 diabetes